Industry trackers reported a marked increase in cash flowing into biotech during JP Morgan week and a late‑year surge in financings. BioCentury noted heightened deal and fund activity tied to conference meetings, while broader market data showed Q4 2025 financing activity rebounded to cap an uneven recovery for the sector. Analysts cite renewed investor appetite for clinical readouts and platform technologies, balanced by selective caution on valuations and M&A timing. The data underscore how concentrated conference weeks can catalyze financings, partnerships and announcements that reshape near‑term capital availability.